Vimarsana
Biggest News Aggregation in the World

Page 17 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

Immunic Inc notes neuroprotective potential of vidofludimus calcium highlighted in preclinical data - Vimarsana News

Immunic Inc notes neuroprotective potential of vidofludimus calcium highlighted in preclinical data

Immunic Inc (NASDAQ:IMUX) has announced the publication of preclinical data highlighting the neuroprotective potential of its investigational drug,...

EQS-News: Immunic, Inc.: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Scientific publication Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program - Vimarsana News

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program

Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming...

Immunic, Inc. (NASDAQ:IMUX) Q1 2023 Earnings Call Transcript - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Q1 2023 Earnings Call Transcript

Jessica Breu: Good morning, and welcome to Immunic's First Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.

Immunic, Inc. (NASDAQ:IMUX) Sees Significant Decrease in Short Interest - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Sees Significant Decrease in Short Interest

Immunic, Inc. (NASDAQ:IMUX – Get Rating) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 3,650,000 shares, a decrease of 14.7% from the April 15th total of 4,280,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest […]

Source: wkrb13.com